An Open-Label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 28 Apr 2017 Status changed from recruiting to completed.
- 16 Feb 2017 Status changed from not yet recruiting to recruiting.
- 24 Jan 2017 New trial record